Trials / Completed
CompletedNCT04317313
18F-FDG PET Radiomics of Diffuse Large B-cell Lymphoma
Synergistic Effect of 18F-FDG PET Radiomics and International Prognostic Index on Outcome Prediction in Diffuse Large B-cell Lymphoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 152 (actual)
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to investigate the prognostic value of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) radiomics in diffuse large B-cell lymphoma (DLBCL) and its additional value to the International Prognostic Index (IPI).
Detailed description
Several studies have shown that 18F-FDG PET radiomics is predictive of survival in DLBCL. However, to the best of the investigator's knowledge, a multi-feature radiomic signature for prognosis assessment of DLBCL has not yet been described. Furthermore, it remains unclear whether PET-based radiomics could add more prognostic values to the IPI in DLBCL. This study aims to develop 18F-FDG PET radiomic signature, and investigate whether the radiomic signature could improve the prognostic value of the IPI score in predicting progression-free survival (PFS) and overall survival (OS) in DLBCL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | FDG PET radiomic feature evaluation | A total of 1245 radiomic features will be calculated and extracted from baseline FDG PET scans. These features include shape features, first order features, textural features and wavelet features. In the second part, based on the results of least absolute shrinkage and selection operator Cox regression algorithm, the most significant radiomic features will be selected to construct the radiomic signature. |
Timeline
- Start date
- 2020-04-01
- Primary completion
- 2021-07-30
- Completion
- 2021-07-30
- First posted
- 2020-03-23
- Last updated
- 2021-10-21
- Results posted
- 2021-06-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04317313. Inclusion in this directory is not an endorsement.